Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report

Blood

Volumn 106, Issue 3, 2005, Pages 925-928

  Galbusera, Miriam ^b   Bresin, Elena ^b   Noris, Marina ^b   Gastoldi, Sara ^b   Belotti, Daniela ^b   Capoferri, Cristina ^b   Daina, Erica ^b   Perseghin, Paolo ^b   Scheiflinger, Friedrich ^b   Fakhouri, Fadi ^b   Grünfeld, Jean Pierre ^b   Pogliani, Enrico ^b   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPHENHYDRAMINE; PARACETAMOL; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CASE REPORT; ENZYME ACTIVITY; HUMAN; MALE; MORBIDITY; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 23044433307     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4885     Document Type: Article

References (25)

1. Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathies. In: Tisher CC, Brenner BM, eds. Renal Pathology With Clinical and Functional Correlations. Philadelphia, PA: J.B. Lippincott Company; 1994:1154-1184.
2. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223-1229.
3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339:1585-1594.
5. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98:1765-1772.
6. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and haemolytic uremic syndrome. Blood. 2002;100:778-785.
7. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004; 124:787-795.
8. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001;85: 1619-1623.
9. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385-391.
10. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105-108.
11. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183-185.
12. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost. 2004;2: 834-836.
13. Fakhouri F, Teixeira L, Delarue R, Grunfeld JP, Veyradier A. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med. 2004;140:314-315.
14. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88:1029-1034.
15. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241-3243.
16. Rieger M, Ferrari S, Herzog A, et al. Quantification of ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies by a newly developed sandwich ELISA. Blood 2004;104:72b.
17. Galbusera M, Benigni A, Paris S, et al. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 1999;10:1234-1241.
18. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57:1140-1143.
19. Ciavarella G, Ciavarella N, Antoncecchi S, et al. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type C). Blood. 1985;66:1423-1429.
20. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow, II: normal B lymphocyte development. Blood 1987; 70:1316-1324.
21. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-4049.
22. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001;113:649-651.
23. Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004;41:34-40.
24. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica. 2004;89:320-324.
25. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005; 84:232-235.